Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. (NASDAQ: CAI) is a patient-centric, next-generation AI TechBio company and precision medicine pioneer whose news flow centers on molecular profiling, precision oncology and data-driven healthcare. Company announcements highlight developments in its comprehensive molecular profiling services, financial results, research collaborations and precision oncology network activities.
Investors and healthcare professionals following CAI news can expect updates on revenue trends and clinical therapy selection case volumes related to molecular profiling services and pharma research and developmental services, as reported in the company’s earnings releases. Caris also issues news on partnerships, such as its collaboration through Caris Discovery with Genentech to identify and validate novel oncology targets in solid tumors, and its partnership with Everlywell to launch the Caris Detect Multi-Cancer Early Detection blood-based screening assay.
Caris frequently reports on activities of the Caris Precision Oncology Alliance, a global network of cancer centers, academic institutions, research consortia and healthcare systems focused on advancing precision oncology and biomarker-driven research. News items include new member institutions joining the alliance, educational initiatives like the Caris POA Fellows Forum, and research presented at major conferences, including multi-study presentations at oncology symposia.
This CAI news page aggregates these press releases and related updates so readers can review company communications on financial performance, collaborations, research output and precision oncology programs in one place. For those tracking the evolution of Caris’ molecular profiling platform, clinico-genomic data assets and AI-driven oncology initiatives, this feed offers a consolidated view of the company’s reported milestones and activities.
Caris Life Sciences (NASDAQ: CAI) reported an interim readout of Achieve 1 for Caris Detect, its multi-cancer early detection blood test using ultra-deep Whole Genome Sequencing and AI. The interim dataset (n=2,122) showed Stage I sensitivity 56.8%, Stage I-II sensitivity 61.3% and specificity 99.1% in an asymptomatic screening subgroup.
Caris held ~865 samples for a blinded validation planned for Q1 2026; development of an updated assay with Whole Transcriptome Sequencing is underway.
Caris Life Sciences (NASDAQ: CAI) reported strong 2025 results with $812.0M revenue, up 97% year-over-year, and Q4 revenue of $292.9M (+125%). Gross margin improved to 66% for FY 2025. The company reported positive Adjusted EBITDA $137.7M and positive free cash flow $66.9M. Caris expects 2026 revenue of $1.0B–$1.02B and reiterated plans to launch Caris Detect in H1 2026.
Caris (NASDAQ: CAI) added a proprietary AI-driven breast cancer signature for capecitabine to its Caris Molecular Tumor Board Report, available with MI Cancer Seek. The signature uses more than 2,000 expression and copy-number features from WES and WTS to predict response in HER2-negative first-line breast cancer.
Caris noted MI Cancer Seek holds FDA approval (Nov 2024) as a WES/WTS-based tissue assay with companion diagnostic indications.
Caris Life Sciences (NASDAQ: CAI) will participate in the TD Cowen 46th Annual Health Care Conference held March 2-4, 2026 in Boston, Massachusetts. The company will present its precision medicine platform, AI/ML-enabled clinico-genomic capabilities, and recent corporate developments to investors and healthcare attendees.
Caris is headquartered in Irving, Texas, with global offices and provides comprehensive molecular profiling services including whole genome, whole exome and whole transcriptome sequencing.
Caris Life Sciences (NASDAQ: CAI) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results.
Investors can join the live webcast at the provided media-server link and access a replay shortly after the call on the company's Investor Relations website.
Caris Life Sciences (NASDAQ: CAI) published a large real-world multiomic study (Jan 28, 2026) analyzing 2,799 trastuzumab deruxtecan (T‑DXd)–treated metastatic breast cancer patients. Whole transcriptome sequencing identified ERBB2 (HER2) and ABCC1 as the strongest transcriptomic predictors of T‑DXd–specific overall survival.
Higher ERBB2 expression aligned with better outcomes; higher ABCC1 correlated with poorer outcomes and increased post‑treatment, alongside enrichment of mutations in ERBB2, NFE2L2, KEAP1 and TOP1, suggesting evolving resistance pathways and actionable insights for drug development.
Caris Life Sciences (NASDAQ: CAI) reported preliminary, unaudited results for Q4 and full year 2025 showing strong growth driven by molecular profiling. For Q4 2025, total revenue was approximately $281 million (+116%), including ~$270 million from Molecular Profiling (with ~$81 million prior-period true-ups), and ~52,700 clinical therapy selection cases (+20%). For full year 2025, total revenue was approximately $800 million (+94%), including ~$755 million from Molecular Profiling (with ~$33 million prior-year true-ups), and ~199,300 cases (+22%). Preliminary cash and marketable securities were ~$802 million as of Dec 31, 2025. Results remain unaudited and subject to change; final results expected with the late-February 2026 earnings release.
Caris Life Sciences (NASDAQ: CAI) announced a partnership with Everlywell to launch Caris Detect, a forthcoming multi-cancer early detection (MCED) blood assay that uses whole genome sequencing (WGS) and AI-driven analysis to identify molecular signals in blood.
The collaboration will distribute Caris Detect via Everlywell's consumer platform and infrastructure; Caris expects to launch the assay in the first half of 2026. Everlywell cites broad reach, having delivered nearly 1 billion personalized health insights and served 60 million people.
Caris Life Sciences (NASDAQ: CAI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Caris will present and participate in a Q&A session on Monday, January 12, 2026 at 1:30 PM PT.
Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com. The company is described as a patient-centric AI TechBio and precision medicine firm using whole exome and whole transcriptome sequencing plus AI to build a multimodal clinico-genomic database and computing platform.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge MA, Tokyo and Basel; media and investor contact emails are provided for inquiries.
Caris Life Sciences (NASDAQ: CAI) announced on December 19, 2025 that Providence Swedish Cancer Institute and the Paul G. Allen Research Center joined the Caris Precision Oncology Alliance (Caris POA).
The addition expands the Caris POA to 99 cancer centers, including 45 NCI-designated centers, and gives members access to Caris' multimodal molecular profiling (genomic, transcriptomic, proteomic) and a clinico-genomic database containing matched molecular and outcomes data from hundreds of thousands of cancer patients.